Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913

Introduction In preclinical data, the combination therapy with S-1 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) had a synergistic antitumor effect on non-small cell lung cancer (NSCLC), regardless of the EGFR mutation status. Patients and Methods Patients with previous...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Invest New Drugs
Main Authors: Nakahara, Yoshiro, Shimokawa, Tsuneo, Misumi, Yuki, Nogami, Naoyuki, Shinkai, Tetsu, Seki, Nobuhiko, Hosomi, Yukio, Hida, Naoya, Okamoto, Hiroaki
Format: Artigo
Sprog:Inglês
Udgivet: Springer US 2020
Fag:
Phase II Studies
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7851018/
https://ncbi.nlm.nih.gov/pubmed/32803700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-00985-4
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker